Study S001139

A Phase III, Multicenter, Randomized, Double Blinded, Parallel-controlled Study Comparing the Efficacy and Safety of HRS9531 Versus Placebo in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin.

ClinicalTrials.gov record

Registration

Registration: NCT07060456
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: TRIPLE
Status: RECRUITING
Enrollment: 300
Start: 2025-07-25
Primary completion: 2027-02
Lead sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
Conditions: Type 2 Diabetes
Interventions: DRUG:HRS9531; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

Change in HbA1c [from baseline to Week 40]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.